Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Short Candidates -- Ignore unavailable to you. Want to Upgrade?

To: prophet_often who wrote (26)	1/24/2001 3:35:41 PM
From: tuck	Read Replies (1) \| Respond to of 897

prophet_often & thread, Revisiting some of the biotechs facing lock-up expiration. In a previous post a couple of weeks ago, I noted that virtually all of them were in the toilet, and that there didn't seem to be much room for more downside. Since then, the market and many biotechs have rallied, while most of the summer IPOs were left behind. Now, with the market looking toppy to me, with rate cuts priced in, I have had a second look and . . . Two exceptions are ILMN and GCOR, which have bounced towards resistance. So those two might be worth a look. Also AMEV, depending on what happens as a result of its analyst meeting this afternoon. But it's seems to be forming a double bottom. Note that MLNM and HGSI are also facing lock-up expirations from their large secondaries. They also could be worth a look. FWIW, bailed on a short-term long on MLNM yesterday. Too early, but I made some change, so I don't mind. Cheers, Tuck